Insiders at Neoleukin Therapeutics, Inc. (NASDAQ:NLTX) have shown a significant appetite for buying shares over the last year, with the CEO making a substantial purchase of US$1m. While this specific purchase was at a lower price than the current market, it indicates insider confidence. Insiders collectively own 22% of the company, suggesting strong alignment with shareholder interests.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
How Much Are Neoleukin Therapeutics, Inc. (NASDAQ:NLTX) Insiders Spending On Buying Shares?
Insiders at Neoleukin Therapeutics, Inc. (NASDAQ:NLTX) have shown a significant appetite for buying shares over the last year, with the CEO making a substantial purchase of US$1m. While this specific purchase was at a lower price than the current market, it indicates insider confidence. Insiders collectively own 22% of the company, suggesting strong alignment with shareholder interests.